Is Vivos Therapeutics going out of business?

Vivos Therapeutics, Inc. (VVOS) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Vivos Therapeutics, Inc. (VVOS) scores 1 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 82.82% (YoY)

Five questions, kept separate

Survival - Critical

1-2 mo of estimated runway from 2026-06-30, based on $1.8M of cash and short-term investments against $17.6M of annual burn. Adjusted shares outstanding increased 82.8% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

-545% net-cash backing support an extreme expectations pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 82.82% (YoY)
• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• FCF margin: -100.92%
• Interest coverage: -6.3x
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.10y
• Return on Assets: -87.68%
• Revenue Quality: High-quality (DSO -11d, Rev +35%)
• Revenue growth YoY: 34.90% (YoY) - Growth from a low base; sustainability uncertain.
• Revenue CAGR (3Y): 2.87%
• Cash Burn Deceleration: -58.75% QoQ improvement (Worsening)
• Revenue per Asset Efficiency: 3.97% QoQ

Read from filings through 2026-08-21.

Price as of 2026-09-07.